title: Is there a role for endothelin-blockade early after coronary artery bypass grafting?
abstract: BACKGROUND
  Diverse results exist regarding myocardial release of endothelin after coronary artery bypass grafting. Because endothelin may be involved in regulation of coronary blood flow, postoperative endothelin-blockade could influence the surgical outcome. In this study, we have evaluated the cardiac outflow of endothelin and effects on coronary flow by endothelin-blockade immediately after completion of the coronary bypass grafting.
  
  
  METHODS
  Thirty patients were subjected to infusions of endothelinA blocker (BQ-123, 260 nmoL/min for up to 30 minutes) or endothelinA blocker and endothelinB blocker (BQ-123 and BQ-788, 260 and 250 nmol/min, respectively, for up to 30 minutes) into a veingraft anastomosed to a coronary vessel, and the coronary blood flow was measured. Plasma levels of endothelin from the coronary sinus and the periphery were determined.
  
  
  RESULTS
  There were no significant changes in flow caused by endothelinA blockade alone or in combination with endothelinB blockade. There were no immediately increased levels of endothelin after surgery or after infusions of the endothelin blockers.
  
  
  CONCLUSIONS
  Endothelin blockade does not influence the immediate perioperative myocardial blood flow after coronary bypass grafting. There is no significantly increased myocardial outflow of endothelin, and endothelin does not have any influence on the basal tone of the coronary vessels in the early phase after coronary bypass grafting.
authors.affiliation: Department of Thoracic Surgery, Karolinska Hospital, Stockholm, Sweden. ulf.lockowandt@ks.se
authors.forename: Ulf
authors.initials: U
authors.lastname: Lockowandt
authors.forename: Anders
authors.initials: A
authors.lastname: Franco-Cereceda
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001026:Coronary Artery Bypass; D003326:Coronary Circulation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000037:antagonists & inhibitors* / Q000097:blood; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage*; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D010880:Piperidines / Q000008:administration & dosage*; D011182:Postoperative Care; D014680:Veins / Q000637:transplantation*
chemical_list: D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; C086539:BQ 788; C072247:cyclo(Trp-Asp-Pro-Val-Leu)